Sedana Medical AB (DE:7D2A)
FRANKFURT:7D2A
7D2A Stock Chart & Stats
€0.90
-€0.09(-6.01%)
At close: 4:00 PM EST
€0.90
-€0.09(-6.01%)
Day’s Range― - ―
52-Week Range€0.58 - €1.52
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€78.39M
Enterprise Value€829.60M
Total Cash (Recent Filing)€90.98M
Total Debt (Recent Filing)€4.70M
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Apr 23, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding99,336,960
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)1.13
Price to Sales (P/S)5.10
P/FCF Ratio-13.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)€20.12M
Bulls Say, Bears Say
Bulls Say
Recurring Consumable RevenueThe business model sells disposable Sedaconda ACD components and the Sedaconda drug, creating per-patient recurring demand. Consumable-driven revenue is structurally sticky in ICU settings, supporting predictable unit volumes and long-term per-patient revenue as hospitals treat ventilated patients.
Strong Revenue Growth & High Gross MarginsSustained top-line growth and ~71% gross margins indicate product-market fit and scalable unit economics. High gross profitability provides structural ability to invest in commercialization and R&D while supporting margin sustainability as volumes scale and fixed costs are leveraged.
Low Leverage And Substantial Equity CapitalA strong balance sheet with minimal debt and sizable equity gives the company durable financial flexibility to fund commercialization, clinical/regulatory work and absorb operating losses without immediate refinancing. This reduces solvency risk and supports medium-term strategic execution.
Bears Say
Persistent Negative Cash FlowConsistent operating and free cash flow deficits mean the company must rely on external financing or equity to fund operations and growth. Persistent cash burn, even if improving, raises dilution and financing risk and can constrain investments in sales, distribution, or regulatory initiatives over coming months.
Ongoing Operating Losses; 2025 DeteriorationDespite revenue gains, escalating net losses show the company has not converted growth into sustainable profits. Structural profitability pressure—likely from commercialization costs or SG&A—can limit return prospects and force strategic trade-offs (cost cuts, slower expansion) if losses persist.
Adoption, Reimbursement And Regulatory DependencyRevenue growth depends on clinical adoption, hospital purchasing and reimbursement dynamics plus regulatory approvals. These external, structural factors can slow market penetration or limit addressable markets, making sales growth and margin realization contingent on outcomes outside the company's direct control.
Sedana Medical AB News
7D2A FAQ
What was Sedana Medical AB’s price range in the past 12 months?
Sedana Medical AB lowest stock price was €0.58 and its highest was €1.52 in the past 12 months.
What is Sedana Medical AB’s market cap?
Sedana Medical AB’s market cap is €78.39M.
When is Sedana Medical AB’s upcoming earnings report date?
Sedana Medical AB’s upcoming earnings report date is Apr 23, 2026 which is in 21 days.
How were Sedana Medical AB’s earnings last quarter?
Sedana Medical AB released its earnings results on Feb 12, 2026. The company reported -€0.009 earnings per share for the quarter, missing the consensus estimate of -€0.006 by -€0.003.
Is Sedana Medical AB overvalued?
According to Wall Street analysts Sedana Medical AB’s price is currently Overvalued.
Does Sedana Medical AB pay dividends?
Sedana Medical AB does not currently pay dividends.
What is Sedana Medical AB’s EPS estimate?
Sedana Medical AB’s EPS estimate is >-0.01.
How many shares outstanding does Sedana Medical AB have?
Sedana Medical AB has 99,336,960 shares outstanding.
What happened to Sedana Medical AB’s price movement after its last earnings report?
Sedana Medical AB reported an EPS of -€0.009 in its last earnings report, missing expectations of -€0.006. Following the earnings report the stock price went down -3.575%.
Which hedge fund is a major shareholder of Sedana Medical AB?
Currently, no hedge funds are holding shares in DE:7D2A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sedana Medical AB
Sedana Medical AB (publ), a medical technology company, develops, markets, and sells medical devices in Sweden and internationally. The company offers Sedaconda ACD-L and Sedaconda ACD-, which are disposable medical devices that enables the administration of volatile anesthetics; Sedaconda Syringe, a 50/60ml syringe; Sedaconda ACD starter kit; FlurAbsorb and FlurAbsorb-S, which are active carbon filters to capture waste anaesthetic gases from the exhaust of the ventilator; FlurAbsorb accessory kit comprising accessories to connect the exhaust of the ventilator and the gas monitor to the FlurAbsorb/FlurAbsorb-S; and FlurAbsorb mount to hold the filter during scavenging of anesthetic gas. It also provides AMG-06 Gas Monitor for continuous non-invasive sidestream monitoring of CO2 and anaesthetics concentration in inspired and expired gases; Sedaconda Filling Adapter, a single-use device for safe and easy extraction of isoflurane from a Sedaconda bottle to a Sedaconda Syringe; and various accessories comprising DRYLINE II Water Traps, WaterLock 2 water trap, Nafion Dryer Tubing, and Respiratory Gas Monitoring Line. Sedana Medical AB (publ) was founded in 1999 and is headquartered in Danderyd, Sweden.
Technical Analysis
Options Prices
Currently, No data available
---